Markets:

Overview

News

Currencies

International

Treasuries

Personalis, Inc. - Common Stock (NQ:PSNL)

6.315 -1.005 (-13.73%)

Streaming Delayed Price Updated: 3:59 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

March 17, 2026

From Personalis, Inc.

Via Business Wire

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

March 12, 2026

From Personalis, Inc.

Via Business Wire

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

February 26, 2026

From Personalis, Inc.

Via Business Wire

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

February 17, 2026

From Personalis, Inc.

Via Business Wire

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026

From Personalis, Inc.

Via Business Wire

Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance

February 10, 2026

From Personalis, Inc.

Via Business Wire

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

February 02, 2026

From Personalis, Inc.

Via Business Wire

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 28, 2026

From Personalis, Inc.

Via Business Wire

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

January 12, 2026

From Personalis, Inc.

Via Business Wire

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

January 08, 2026

From Personalis, Inc.

Via Business Wire

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

December 17, 2025

From Personalis, Inc.

Via Business Wire

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

December 11, 2025

From Personalis, Inc.

Via Business Wire

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 18, 2025

From Personalis, Inc.

Via Business Wire

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

November 10, 2025

From Personalis, Inc.

Via Business Wire

Personalis Reports Third Quarter 2025 Financial Results

November 04, 2025

From Personalis, Inc.

Via Business Wire

Personalis to Announce Third Quarter 2025 Financial Results

October 21, 2025

From Personalis, Inc.

Via Business Wire

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

October 16, 2025

From Personalis, Inc.

Via Business Wire

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 15, 2025

From Personalis, Inc.

Via Business Wire

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

September 10, 2025

From Personalis, Inc.

Via Business Wire

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

September 03, 2025

From Personalis, Inc.

Via Business Wire

Personalis to Participate in Upcoming Investor Conferences

August 27, 2025

From Personalis, Inc.

Via Business Wire

Personalis Reports Second Quarter 2025 Financial Results

August 05, 2025

From Personalis, Inc.

Via Business Wire

Personalis to Announce Second Quarter 2025 Financial Results

July 22, 2025

From Personalis, Inc.

Via Business Wire

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025

From Personalis, Inc.

Via Business Wire

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

July 09, 2025

From Personalis, Inc.

Via Business Wire

Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

June 03, 2025

From Personalis, Inc.

Via Business Wire

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

June 02, 2025

From Personalis, Inc.

Via Business Wire

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

May 22, 2025

From Personalis, Inc.

Via Business Wire

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 14, 2025

From Personalis, Inc.

Via Business Wire

Personalis Reports First Quarter 2025 Financial Results

May 06, 2025

From Personalis, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.